Table 3

Descriptive analysis of LLT at baseline, and mean change after 12 weeks of follow-up, according to type of patient

Patients not at their LDL-C goal on maximum tolerated dose of LLT at baseline (n=127)Baseline12 weeks95% CI
n (%)n (%)Mean LDL-C change ±SD (mg/dL)
n=127n=127n=91
 Alirocumab monotherapy26 (20.5)23 (18.1)−48.0±14.1−57.5 to −37.7
 Alirocumab + statin60 (47.2)51 (40.2)−50.0±23.2−67.9 to −35.0
 Alirocumab + other LLT21 (16.5)21 (16.5)−56.3±11.4−62.7 to −45.5
 Alirocumab + statin + other LLT20 (15.7)32 (25.2)−53.8±17.5−62.7 to −40.3
Patients with statin intolerance or contraindication at baseline (n=128)n=128n=128n=64
 Alirocumab monotherapy37 (28.9)32 (25.0)−48.2±13.4−57.4 to −40.4
 Alirocumab + statin52 (40.6)45 (35.2)−43.2±22.4−58.9 to −28.5
 Alirocumab + other LLT29 (22.7)30 (23.4)−56.3±11.4−62.7 to −45.5
 Alirocumab + statin + other LLT10 (7.8)21 (16.4)−45.0±10.2−51.6 to −39.4
Patients not at goal or with statin intolerance/contraindication at baseline (n=175)n=175n=175n=94
 Alirocumab monotherapy41 (23.4)36 (20.6)−48.3±13.3−57.4 to −40.4
 Alirocumab + statin82 (46.9)71 (40.6)−50.3±23.0−66.9 to −36.2
 Alirocumab + other LLT29 (16.6)30 (17.1)−56.3±11.4−62.7 to −45.5
 Alirocumab + statin + other LLT23 (13.1)38 (21.7)−53.8±17.5−62.7 to −40.3
  • LDL-C, low density lipoprotein cholesterol; LLT, lipid-lowering therapy.